Evidence map›Paper›PMID 39708059›Full record

ArticleInfectious diseases and therapy2025

Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States.

Amanda Wilson, Neloufar Rahai, Ekkehard Beck, Elisha Beebe, Brian Conroy, Daina Esposito, Priya Govil, Hagit Kopel, Tianyi Lu, James Mansi and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infectious diseases and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Amanda WilsonModerna, Inc., 325 Binney St., Cambridge, MA, 02142, USA. Amanda.Wilson@modernatx.com.ORCID http://orcid.org/0000-0003-4430-560X
Neloufar RahaiAetion, New York, NY, USA.
Ekkehard BeckModerna, Inc., 325 Binney St., Cambridge, MA, 02142, USA.
Elisha BeebeAetion, New York, NY, USA.
Brian ConroyAetion, New York, NY, USA.
Daina EspositoModerna, Inc., 325 Binney St., Cambridge, MA, 02142, USA.
Priya GovilAetion, New York, NY, USA.
Hagit KopelModerna, Inc., 325 Binney St., Cambridge, MA, 02142, USA.
Tianyi LuModerna, Inc., 325 Binney St., Cambridge, MA, 02142, USA.
James MansiModerna, Inc., 325 Binney St., Cambridge, MA, 02142, USA.
Morgan A Marks *Moderna, Inc., 325 Binney St., Cambridge, MA, 02142, USA.
Katherine E MuesAetion, New York, NY, USA.
Rohan ShahAetion, New York, NY, USA.
Michelle SkornickiAetion, New York, NY, USA.
Tianyu SunModerna, Inc., 325 Binney St., Cambridge, MA, 02142, USA.
Astra ToyipAetion, New York, NY, USA.
Mitra YousefiModerna, Inc., 325 Binney St., Cambridge, MA, 02142, USA.
David Martin *Moderna, Inc., 325 Binney St., Cambridge, MA, 02142, USA.
Andre B AraujoModerna, Inc., 325 Binney St., Cambridge, MA, 02142, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn September 2023 the Food and Drug Administration (FDA) approved an updated mRNA COVID-19 vaccine targeting the XBB.1.5 sublineage. This study evaluates the effectiveness of mRNA-1273.815, a 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine in preventing COVID-19-related hospitalizations and medically attended COVID-19 in US adults aged ≥ 18 years.

methodsThis observational, matched cohort study used medical and pharmacy claims data from HealthVerity. Adults vaccinated with mRNA-1273.815 between September 12, 2023, and December 31, 2023, were followed through January 26, 2024. Vaccinated individuals were matched with individuals unvaccinated with any 2023-2024 COVID-19 vaccine on demographic and clinical characteristics. The primary and secondary outcomes were COVID-19 hospitalization and medically attended COVID-19, respectively. Inverse probability of treatment weighting and Cox proportional hazards regression were utilized to estimate vaccine effectiveness (VE).

resultsThe study included 1,272,161 vaccinated individuals matched 1:1 with unvaccinated individuals, with a maximum follow-up of 128 (median 84) days. The VE against COVID-19 hospitalization was 51% (95% confidence interval [CI]: 48-54%). Subgroup analyses showed a VE of 56% (95% CI 51-61%) among adults ≥ 65 years and 46% (95% CI 39-52%) in immunocompromised adults. For medically attended COVID-19, the VE was 25% (95% CI 24-27%). Time-varying analyses showed that while VE declined over time, VE remained significant.

conclusionDuring the 2023-2024 respiratory season, the mRNA-1273.815 vaccine significantly protected against COVID-19-related hospitalizations and medically attended COVID-19 across diverse adult populations and demonstrated durability of the effect. These results support the continued use of updated COVID-19 vaccines to mitigate severe outcomes and maintain public health safety.

Indexed as

COVID-19 vaccineHospitalizationMedically attended COVID-19MRNA-1273.815Vaccine effectiveness

Identifiers

PMID39708059
PMCPMC11782792

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.